Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Otsuka Pharmaceutical
Biotech
UPDATED: Taiho’s discontinues ph. 3 trial after DMD miss
Taiho said both cohorts of the trial have been discontinued and that it is considering all possibilities regarding the future of TAS-205.
Gabrielle Masson
Jul 8, 2025 10:17am
Otsuka's $670M pact to point Harbour's TCE to autoimmune disease
Jun 23, 2025 6:29am
Otsuka's kidney disease drug halves UPCR levels in ph. 3 study
Jun 6, 2025 6:26am
Otsuka's Taiho pays $400M to buy Swiss ADC partner
Mar 17, 2025 8:10am
Otsuka's kidney disease drug improves UPCR levels in ph. 3 trial
Oct 22, 2024 10:38am
Otsuka pays $800M for Jnana and its clinical-stage PKU drug
Aug 1, 2024 5:55am
